乳腺癌患者血清癌胚抗原、胰腺激素抑制因子和组织多肽抗原作为肿瘤标志物的比较。

Comparison of serum CEA, PHI, and TPA as tumor markers in breast cancer patients.

作者信息

Paulick R, Caffier H, Paulick M

出版信息

Cancer Detect Prev. 1987;10(3-4):197-203.

Abstract

The purpose of this study was to evaluate the clinical significance of different serum tumor markers in patients with breast cancer who developed recurrent disease. Determined were tissue polypeptide antigen (TPA), carcinoembryonic antigens (CEA), and phosphohexose isomerase (PHI). Serum samples of 411 breast cancer patients with either locoregional or metastatic recurrence were analyzed. Positive rates of all three markers depended on the clinical stage of the disease, with highest rates of elevated titers in advanced disease. In comparison, CEA and TPA are more sensitive markers than PHI. According to the site of recurrence, CEA exhibited the highest rate of elevated titers in patients with bone metastases and PHI in patients with visceral metastases. Using PHI in combination with CEA, sensitivity (ie, at least one marker is elevated) was increased by 6-20% compared to the results obtained with single marker analysis. However, for easier interpretation of the tumor marker results in clinical practice, it may be helpful to employ a product value of CEA and PHI.

摘要

本研究的目的是评估不同血清肿瘤标志物在发生复发性疾病的乳腺癌患者中的临床意义。检测了组织多肽抗原（TPA）、癌胚抗原（CEA）和磷酸己糖异构酶（PHI）。分析了411例局部或转移性复发的乳腺癌患者的血清样本。所有这三种标志物的阳性率取决于疾病的临床分期，晚期疾病中滴度升高的发生率最高。相比之下，CEA和TPA比PHI更敏感。根据复发部位，CEA在骨转移患者中滴度升高的发生率最高，而PHI在内脏转移患者中最高。与单标志物分析结果相比，将PHI与CEA联合使用时，敏感性（即至少一种标志物升高）提高了6%至20%。然而，为了在临床实践中更便于解释肿瘤标志物结果，采用CEA和PHI的乘积值可能会有所帮助。